Videos & Webinars - European Medical Journal

Continue

Video & Webinars

Hematology
26 Jun 2015

The crucial roles of GFI1B in platelet development

The identification of eight new Growth Factor Independence 1B (GFI1B) variants in families with bleeding and platelet disorders may result in the…
Hematology
26 Jun 2015

Pacritinib therapy led to symptom improvement in myelofibrosis

The phase 3 PERSIST-1 study showed that pacritinib, a selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3), is more…
Hematology
26 Jun 2015

Treatment and outcome of CML patients from the EUTOS population-based registry

The European Treatment Outcome Study (EUTOS) investigated the treatment and treatment outcome of patients with chronic myeloid leukaemia (CML).
Hematology
26 Jun 2015

Venetoclax (ABT-199/GDC-0199) plus rituximab shows promise in relapsed/refractory CLL

n a phase 1b, open-label, dose-escalation, multicentre study of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), the combination…
Hematology
26 Jun 2015

Adding elotuzumab to standard treatment for myeloma reduced disease progression

ELOQUENT-2, a phase 3, randomised, open-label study of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory…
EMJ
Oncology
26 Jun 2015

Phase 3 CheckMate 067 trial of nivolumab in previously untreated advanced melanoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, Consultant Medical Oncologist at The Royal Marsden…
EMJ
Oncology
26 Jun 2015

Whole Brain Radiation Therapy is More Harmful Than Beneficial for Small Brain Metastases

In the phase 3 NCCTG N0574 (Alliance) trial, patients with 1 to 3 small brain metastases were randomised to receive stereotactic radiosurgery (SRS) alone…
EMJ
Oncology
26 Jun 2015

Elective Neck Dissection Improved Survival in Early Node-Negative Oral Cancer

A phase 3, randomised controlled trial showed that elective neck dissection improved overall survival by 12.5% and reduced risk of death by 36% when…